Effects of nicorandil on the reduction of BNP levels in patients with chronic kidney disease

Tomonori Kimura, Harumi Kitamura, Kazunori Inoue, Noritaka Kawada, Isao Matsui, Yasuyuki Nagasawa, Yoshitsugu Obi, Maki Shinzawa, Yasuhiko Sakata, Takayuki Hamono, Hiromi Rakugi, Yoshitaka Isaka

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Patients with chronic kidney disease (CKD) still frequently experience cardiovascular events despite recent progress in treatment. We examined whether nicorandil, a hybrid nitrate and adenosine triphosphate- sensitive potassium channel opener, could improve a biomarker and physiological markers of cardiovascular events. Methods: Patients with advanced stage CKD (stage III-V with or without peritoneal dialysis) were included in this trial if they were considered at high risk for cardiovascular events [past history of cardiovascular diseases, past history of coronary angiography, presence of endothelial dysfunction measured by reactive hyperemia peripheral arterial tonometry, and presence of high brain natriuretic peptide (BNP) values]. Patients were randomly assigned to be treated with or without oral nicorandil, 15 mg/day. BNP values and endothelial function (augmentation index, pulse wave velocity, and reactive hyperemia peripheral arterial tonometry) before and 1 month after the initiation of the trial were assessed. Results: Nineteen patients (15 men, 4 women) with a mean age of 61 ± 10 (SD) years were included. The median baseline BNP value was 75.3 (interquartile range, 32.1-138.8) pg/ml, and the BNP level was significantly reduced in the nicorandil group (P < 0.05). Regression analysis demonstrated that only the use of nicorandil is related to a decrease of BNP levels [standardized β coefficient, -75.1 (95% CI, -19.7 to -130.6), P = 0.01]. There were no significant changes in the rest of the parameters in the nicorandil group in comparison to the control group. The change in BNP levels was correlated with changes in the augmentation index (P < 0.01) and central pulse pressure (P = 0.03). Conclusions: Nicorandil treatment may reduce the level of BNP by reducing the central blood pressure in CKD patients.

Original languageEnglish
Pages (from-to)854-860
Number of pages7
JournalClinical and experimental nephrology
Volume15
Issue number6
DOIs
Publication statusPublished - 2011 Dec 1
Externally publishedYes

Keywords

  • Brain natriuretic peptide (BNP)
  • Chronic kidney disease (CKD)
  • Endothelial function
  • Nicorandil
  • Peritoneal dialysis (PD)

ASJC Scopus subject areas

  • Physiology
  • Nephrology
  • Physiology (medical)

Fingerprint Dive into the research topics of 'Effects of nicorandil on the reduction of BNP levels in patients with chronic kidney disease'. Together they form a unique fingerprint.

  • Cite this

    Kimura, T., Kitamura, H., Inoue, K., Kawada, N., Matsui, I., Nagasawa, Y., Obi, Y., Shinzawa, M., Sakata, Y., Hamono, T., Rakugi, H., & Isaka, Y. (2011). Effects of nicorandil on the reduction of BNP levels in patients with chronic kidney disease. Clinical and experimental nephrology, 15(6), 854-860. https://doi.org/10.1007/s10157-011-0522-1